Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
NASDAQNVAX
Recent News
Jul 1, 2022

Novavax is awaiting US emergency use authorization for our prototype COVID-19 vaccine and we are committed to bringing it to market. Clinical data generated to-date demonstrate that this prototype...

Learn more

Jun 28, 2022

Novavax prototype vaccine (NVX-CoV2373) demonstrates broad immune responses including against Omicron and other circulating variants Pre-clinical data demonstrated that boosting with Novavax'...

Learn more

Jun 28, 2022

Novavax is pleased to be one of three companies invited to participate in the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC)...

Learn more

All press releases

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.